December 22, 2025 — Leads & Copy —
Niagen Bioscience, Inc. (NASDAQ: NAGE) has acquired a comprehensive portfolio of patents covering nicotinamide riboside (NR) and its salt forms from Queen’s University Belfast (QUB).
The acquisition strengthens Niagen Bioscience’s leadership and ownership position in NAD+ precursor intellectual property.
The acquired portfolio includes patents underpinning the production, composition, and commercial use of NR, encompassing composition-of-matter patents covering crystal morphologies, methods of making NR and other NAD+ precursors, and global patent rights across multiple jurisdictions.
Before the transaction, Niagen Bioscience held exclusive rights to these patents through licensing and joint ownership arrangements with QUB. Niagen Bioscience is now the sole owner of this IP portfolio.
Rob Fried, Chief Executive Officer of Niagen Bioscience, said the transaction consolidates the most important intellectual property underlying their NR business into Niagen Bioscience outright.
Fried added that composition-of-matter patents are the strongest form of IP protection, and owning this portfolio further protects Niagen Bioscience shareholders against infringers of all known forms of NR.
The acquired patents include those disclosed by the Company in March 2025, including U.S. Patent No. 12,252,506, which covers the composition of matter for multiple NR salt forms—such as NR Malate and NR Tartrate—as well as other NR derivatives.
With the acquisition, Niagen Bioscience gains financial, strategic and operational flexibility, greater control over the molecules it advances across current and future applications, including the ones that the Company plans to use for pharmaceutical applications.
This also represents increased optionality in how the intellectual property is developed, partnered, or licensed.
The Company’s intellectual property estate includes more than 90 issued and pending patents worldwide across NR and other NAD+ precursors, including over 50 issued and pending patents focused solely on NR.
Niagen Bioscience continuously evaluates next-generation NAD+ precursors while maintaining the category’s most robust and defensible IP position.
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of scientists, works with independent investigators from universities and research institutions to uncover the full potential of NAD+.
Niagen® (patented nicotinamide riboside, or NR) powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States.
Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.
For additional information on the IP and clinical research behind Niagen, visit www.niagenbioscience.com.
Source: Niagen Bioscience
